. Author manuscript; available in PMC: 2023 Jun 22.

Published in final edited form as: Expert Opin Investig Drugs. 2020 Sep 9;29(9):935–945. doi: 10.1080/13543784.2020.1795639

Table 2.

Summary of major clinical trials of integrin inhibitors for age-related macular degeneration and diabetic macular edema.

Drug/Company	Target Integrin Receptor(s)	Indication	Trial Stage	Status
Risuteganib/Allegro Ophthalmics	α_vβ₃, α_vβ₅, α₅β₁, and α₅β₃	DME Dry AMD/GA	Ph 2	Completed
			Ph 2	Completed
THR-687/Oxurion	α_vβ₃, α_vβ₅ and α₅β₁	DME	Ph 1	Completed
SF-0166/SciFluor Life Sci.	α_vβ₃, α_vβ₆, and α_vβ₈	AMD	Ph 1/2	Completed
		DME	Ph 1/2	Completed
Volociximab/Ophthotech Corporation (now Iveric Bio)	α₅β₁	subfoveal CNV secondary to AMD	Ph 1	No further clinical studies announced
JSM-6427/Jerini AG & Shire Pharmaceuticals (now Takeda Pharma)	α₅β₁	AMD	Ph 1	No further clinical studies announced

DME, diabetic macular edema; AMD, age-related macular degeneration; CNV, choroidal neovascularization.